ARTL · Artelo Biosciences, Inc.
$2.62
+0.00 (+0.08%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.36M
Shares
510,563
Volume · Oct 21
750
Avg daily vol (36 sessions)
811.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.62
Open$2.70
Day$2.62–2.80
52W close$2.62–104.76
Avg vol 30d948K
Short int46K · 9.0% float · 1.0d
Short vol35%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$12.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.20M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,319.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
9.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−89%
below
Price vs 50-day avg
−47%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−91%
trailing
YTD return
−92%
this year
Relative strength
−100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
1 of 10 funds reported for Sep 30 · net +1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.04% of float · ▲ +104.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
281%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
21.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−89%
Bearish
Price vs 50-day avg
−47%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
1 of 10 funds reported for Sep 30 · net +1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.04% of float · ▲ +104.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $105
vs 200-day avg -89%
vs 50-day avg -47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARTL
this stock
Artelo Biosciences, Inc.
|
$1.36M | — | — | — | 9.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 9, 2026
- This year
- 35
Artelo Biosciences is among approximately 180 Nasdaq-listed companies initially below the new $5,000,000 MVLS threshold. A temporary stay was announced July 29, 2026, and Nasdaq proposed delaying the rule until the stay ends, with comments due October 29, 2026.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARTL | -12.1% | -36.9% | -91.5% | -35.2% | -92.1% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -10.9% | -36.3% | -99.5% | -36.0% | -104.8% |